This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Agile Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Agile Therapeutics.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.6% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25
Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Agile Therapeutics onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2024 | 22 | -16 | -2 | -2 | N/A |
| 3/31/2024 | 21 | -8 | -10 | -10 | N/A |
| 12/31/2023 | 20 | -14 | -10 | -10 | N/A |
| 9/30/2023 | 20 | -14 | -11 | -11 | N/A |
| 6/30/2023 | 16 | -19 | -28 | -28 | N/A |
| 3/31/2023 | 13 | -20 | -23 | -23 | N/A |
| 12/31/2022 | 11 | -25 | -36 | -36 | N/A |
| 9/30/2022 | 8 | -41 | -51 | -51 | N/A |
| 6/30/2022 | 7 | -52 | -53 | -53 | N/A |
| 3/31/2022 | 6 | -64 | -66 | -65 | N/A |
| 12/31/2021 | 4 | -71 | -65 | -65 | N/A |
| 9/30/2021 | 3 | -69 | -66 | -66 | N/A |
| 6/30/2021 | 2 | -68 | -63 | -63 | N/A |
| 3/31/2021 | 1 | -61 | -54 | -54 | N/A |
| 12/31/2020 | 1 | -52 | -48 | -47 | N/A |
| 9/30/2020 | N/A | -40 | -34 | -33 | N/A |
| 6/30/2020 | N/A | -29 | -23 | -23 | N/A |
| 3/31/2020 | N/A | -22 | -19 | -19 | N/A |
| 12/31/2019 | N/A | -19 | -16 | -16 | N/A |
| 9/30/2019 | N/A | -16 | -16 | -16 | N/A |
| 6/30/2019 | N/A | -16 | -14 | -14 | N/A |
| 3/31/2019 | N/A | -18 | -16 | -16 | N/A |
| 12/31/2018 | N/A | -20 | -17 | -17 | N/A |
| 9/30/2018 | N/A | -22 | -20 | -20 | N/A |
| 6/30/2018 | N/A | -26 | -24 | -23 | N/A |
| 3/31/2018 | N/A | -28 | N/A | -24 | N/A |
| 12/31/2017 | N/A | -28 | N/A | -25 | N/A |
| 9/30/2017 | N/A | -27 | N/A | -22 | N/A |
| 6/30/2017 | N/A | -28 | N/A | -22 | N/A |
| 3/31/2017 | N/A | -29 | N/A | -23 | N/A |
| 12/31/2016 | N/A | -29 | N/A | -23 | N/A |
| 9/30/2016 | N/A | -27 | N/A | -25 | N/A |
| 6/30/2016 | N/A | -29 | N/A | -25 | N/A |
| 3/31/2016 | N/A | -29 | N/A | -27 | N/A |
| 12/31/2015 | N/A | -30 | N/A | -25 | N/A |
| 9/30/2015 | N/A | -33 | N/A | -26 | N/A |
| 6/30/2015 | N/A | -30 | N/A | -26 | N/A |
| 3/31/2015 | N/A | -25 | N/A | -21 | N/A |
| 12/31/2014 | N/A | -16 | N/A | -15 | N/A |
| 9/30/2014 | N/A | -12 | N/A | -11 | N/A |
| 6/30/2014 | N/A | -9 | N/A | -7 | N/A |
| 3/31/2014 | N/A | -10 | N/A | -8 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if AGRX's forecast earnings growth is above the savings rate (2.5%).
Winst versus markt: Insufficient data to determine if AGRX's earnings are forecast to grow faster than the US market
Hoge groeiwinsten: Insufficient data to determine if AGRX's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if AGRX's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: Insufficient data to determine if AGRX's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if AGRX's Return on Equity is forecast to be high in 3 years time